Current chemotherapeutic treatment of malignant pleural mesothelioma

Anna Nowak, M.J. Bryne, Michael Millward, J.M. Alvarez, Bruce Robinson

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)


Malignant pleural mesotheliorna is an aggressive malignancy which is almost always fatal; median survival is usually < 1 year. Most patients present with symptorns including pain, dyspnoea, pleural effusions and chest wall masses. Until recently, there has been no effective treatment which can improve symptoms and prolong survival. This article reviews recent developments in the treatment of mesothelioma, particularly advances in drug therapy and the use of the current most active drug combination: pemetrexed and cisplatin. Pemetrexed is a novel antifolate drug with multiple enzyme targets. The combination of pernetrexed and cisplatin demonstrated a survival advantage over cisplatin alone in patients with pleural mesothelioma, and can give symptomatic benefits. This combination has become the standard of care in mesothelioma treatment.
Original languageEnglish
Pages (from-to)1-9
JournalExpert Opinion on Pharmacotherapy
Issue number12
Publication statusPublished - 2004


Dive into the research topics of 'Current chemotherapeutic treatment of malignant pleural mesothelioma'. Together they form a unique fingerprint.

Cite this